Wealth Enhancement Advisory Services’s BridgeBio Pharma BBIO Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	13,202 +8,250	+167%	+$578K	﹤0.01%	1988
2026 Q1	$362K	Buy	4,952 +447	+10%	+$32.4K	﹤0.01%	2602
2025 Q4	$333K	Buy	4,505 +130	+3%	+$8.53K	﹤0.01%	2834
2025 Q3	$237K	Buy	+4,375	New	+$213K	﹤0.01%	2981

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Wealth Enhancement Advisory Services's BBIO Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its BridgeBio Pharma (BBIO) stake by 167% in Q2 2026, buying an estimated $578K and bringing the position to 13,202 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1988.

Wealth Enhancement Advisory Services first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 40 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Wealth Enhancement Advisory Services held 13,202 shares of BridgeBio Pharma worth $1.13M as of Q2 2026.
Wealth Enhancement Advisory Services bought 8,250 BridgeBio Pharma shares in Q2 2026, an estimated $578K.
BridgeBio Pharma made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1988 holding.
Wealth Enhancement Advisory Services first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
40 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.